HeartSciences

27 articles about HeartSciences

• HeartSciences Expands its Scientific Advisory Board

  2/12/2024

  Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

• HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.

  9/25/2023

  Heart Test Laboratories, Inc.  d/b/a HeartSciences today announced that Company CEO, Andrew Simpson, will present at Maxim Group’s Virtual Tech Conference Series: Emerging Growth in A.I on Wednesday, September 27th, 2023, at 10:30 a.m. ET.

• HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

  5/9/2023

  Heart Test Laboratories, Inc. today announces completion of patient enrollment for its MyoVista wav ECG pivotal study for FDA De Novo submission.

• HeartSciences to Participate at the Inaugural EF Hutton Global Conference

  5/8/2023

  Heart Test Laboratories, Inc. today announces that CEO, Andrew Simpson, will participate at the Inaugural EF Hutton Global Conference being held May 10 – 11, 2023, at the Plaza Hotel in New York City.

• HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023

  4/17/2023

  Heart Test Laboratories, Inc.   d/b/a HeartSciences today announces that CEO Andrew Simpson will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023.

• HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease

  2/6/2023

  Heart Test Laboratories, Inc. today announced it has been granted a patent in Israel (Patent No. 10-2490960) from the Israel Patent Office.

• HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive

  1/4/2023

  Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of Artificial Intelligence, announced it has appointed David R. Wells to its Board of Directors, effective December 28, 2022.

• HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results

  12/16/2022

  Heart Test Laboratories, Inc.d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) today provided a business update and reported financial results for the fiscal 2023 second quarter ended October 31, 2022.

• HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022

  11/28/2022

  Heart Test Laboratories, Inc.d/b/a HeartSciences (NASDAQ: HSCS; HSCSW)(“HeartSciences” or the “Company”) today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be presenting at the 2022 RHK Disruptive Growth Conference being held December 5-6, 2022 at the offices of Reed Smith in New York City.

• HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022

  11/21/2022

  Heart Test Laboratories, Inc.   d/b/a HeartSciences today announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating at the at the 11th Annual Benchmark Discovery One-on-One Investor Conference.

• HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

  10/19/2022

  Heart Test Laboratories, Inc. d/b/a HeartSciences reports that the American Medical Association has issued new industry-first Category III Current Procedural Terminology codes for novel AI assistive algorithmic ECG risk assessment for cardiac dysfunction.

• HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th

  10/6/2022

  Heart Test Laboratories, Inc. today announced that Andrew Simpson, Chairman and Chief Executive Officer of HeartSciences, has been invited to present at the 2022 MicroCap Rodeo Windy City Roundup Conference, which is being held on October 12 - 13, 2022 in Chicago, Illinois.

• HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial IntelligencePatent continues to strengthen and expand IP portfolio

  9/20/2022

  Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), today announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods. 

• HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

  9/12/2022

  Heart Test Laboratories, Inc d.b.a HeartSciences announced that management has been invited to participate and showcase the company’s technology at the Inauguration Ceremony of the Center for Innovation at the Rutgers Robert Wood Johnson University Hospital on September 14, 2022, in New Brunswick, New Jersey.

• HeartSciences Showcases MyoVista® Wavelet ECG at 2018 Scientific Sessions of the American Heart Association (AHA)

  11/7/2018

  Booth 421 next to the Health Innovation Pavilion

• HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine

  9/4/2018

  Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018.

• HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)

  8/20/2018

  The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018.

• HeartSciences Named “Start-Up to Watch”

  6/22/2018

  “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist.

• HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

  5/2/2018

  HeartSciences announced that Peter W. Macfarlane has joined its board of clinical advisors.

• HeartSciences Showcases High Sensitivity ECG at 2018 Arab Health Meeting

  1/22/2018

  HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 Arab Health show at the Dubai International Convention and Exhibition Centre in Dubai, UAE, 29 January through 01 February, 2018.